Skip to content
Medical Health Aged Care, Research Development

NeuRA launches world’s largest clinical trial for phantom limb pain

NeuRA (Neuroscience Research Australia) 2 mins read

Key points

  • NeuRA is now recruiting for TITAN, the world’s largest clinical trial to date into potential treatments phantom limb pain.  
  • Phantom limb pain is a condition that baffles scientists and affects up to 80% of people who have undergone limb amputation.
  • The trial will investigate the effectiveness of two drug-free treatments that aim to provide meaningful pain relief.

Exploring two new treatments

Researchers at NeuRA’s Centre for Pain Impact are carrying out world’s largest clinical trial for two potential treatments for phantom limb pain.

Phantom limb pain is a distressing and disabling condition that has baffled scientists and clinicians and affects up to 80% of people who have had a limb amputated or had a spinal cord injury.

NeuRA Senior Research Scientist and Director of the Centre for Pain Impact, Professor James McAuley, said the TITAN clinical trial would investigate the effectiveness of two promising treatments.

“There are currently no proven treatments that provide meaningful pain relief for people with phantom limb pain,” Prof McAuley said.

“This is a randomised clinical trial funded by the Commonwealth Government with the aim of reducing pain and improving function. Both treatments we are investigating are drug-free and aim to change how the brain processes pain signals coming from body. The first is a progressive rehabilitation program using techniques such as mirror therapy, while the second uses low frequency non-invasive neuromodulation.”

 

What is phantom limb pain?

Phantom limb pain is used to describe sensations in a body part that is no longer present. This may include feeling that the ‘phantom’ limb is in a specific position or shape, is moving, is warm or cold, is itching, tingling or an electric sensation.

Phantom limb pain most commonly occurs in people after a major limb amputation and often leads to social isolation and loss of independence,” Prof McAuley said.

“At its worst, the condition can cause unbearable symptoms, including intense burning, shooting, stabbing, crushing, and electric shock type sensations that can disrupt sleep and lead to depression and a loss of quality of life. In many cases, the symptoms last a lifetime with little, as most analgesic medicines have only small effects and are accompanied by significant side effects. We want to find treatments than can provide meaningful pain relief.”

Join the world's largest clinical trial

Researchers from NeuRA’s Centre for Pain Impact will run the randomised clinical trial. This is a large-scale, Australia-wide initiative that will be conducted online by physiotherapists, ensuring it is widely accessible.

“We’re now encouraging people who suffer from phantom-limb pain to join our trial,” Prof McAuley said.

To find out more or register interest, visit: https://neura.edu.au/project/titan-a-clinical-trial-for-phantom-limb-pain

ENDS

 

 


About us:

About NeuRA

Neuroscience Research Australia (NeuRA) is an independent, not-for-profit research institute based in Sydney aiming to prevent, treat and cure brain and nervous system diseases, disorders and injuries through medical research.

 To learn more about NeuRA: www.neura.edu.au


Contact details:

Media Contacts
Katana Smith
Senior Media and PR Advisor
0452 140 477
[email protected]

Beatrix Kates 
Director of Communications
0421 320 769
[email protected]

 

Media

More from this category

  • Medical Health Aged Care
  • 06/03/2026
  • 19:10
Claritas HealthTech Ltd

Claritas iPET(TM) Approved by Australia TGA to Supply the Medical Software Device for Image Processing Enabling Diagnostic Quality Images from Short Scan Time and/or Low Dose PET, PET-CT/MRI Scans

LONDON and SYDNEY, March 06, 2026 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art image enhancement, noise reduction, segmentation and quantification, and related AI technologies, is pleased to announce that the Australian regulatory agency for medicines and medical devices, namely, the Therapeutic Goods Administration (TGA) has approved the software device, Claritas iPET™ for supply in Australia.This clearance from TGA in Australia further expands the reach and use of Claritas iPET™, already cleared and used in several jurisdictions. This software tool which is agnostic to equipment type and manufacturer, and which integrates into existing hospital…

  • Medical Health Aged Care
  • 06/03/2026
  • 15:57
Dementia Australia

Cronulla comes together for people impacted by dementia

Friday 6 March 2026 Cronulla comes together for people impacted by dementia Cronulla community members tied up their laces and showed up in force last weekend for the 2026 Cronulla Memory Walk & Jog - throwing their support behind people impacted by dementia whilst getting active to improve their brain health. More than 760 people walked, ran and jogged to the finish line to raise an impressive total of $103,430. Dementia Australia CEO Professor Tanya Buchanan extended her gratitude to all who participated, volunteered and raised vital funds for the cause. “There was an incredible turnout from the Cronulla community…

  • Contains:
  • Medical Health Aged Care
  • 06/03/2026
  • 12:06
Royal Australian College of GPs

TGA ignored as Victorian Government ‘shortcut’ puts women at risk: RACGP

The Royal Australian College of GPs (RACGP) has expressed disappointment that the Victorian Government has overridden repeated warnings from the Therapeutic Goods Administration (TGA) by allowing pharmacists to prescribe the contraceptive pill, undermining established medicines safety safeguards. The Victorian Government has, contrary to repeated TGA assessments, weakened its medicines safety regulations by enabling pharmacists, rather than medically trained prescribers, to initiate prescriptions for the oral contraceptive pill. RACGP Victoria Chair Dr Anita Muñoz said the announcement prioritises political expediency and industry lobbying over evidence‑based public health. “We are deeply disappointed that the Victorian Government appears to be listening to lobbyists…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.